Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 8/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170915 | 0.93 | FURIN (0.35) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22767956 | 0.90 | FURIN (0.34) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21534490 | 0.90 | FURIN (0.34) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24336901 | 0.86 | LMNA (0.35) | FURINPOLB | |
| SCHEMBL25488906 | 0.86 | LMNA (0.35) | FURINPOLB | |
| SCHEMBL12629537 | 0.85 | FURIN (0.37) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL12568288 | 0.85 | FURIN (0.37) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL15870198 | 0.85 | SMN1; SMN2 (0.43) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL30697716 | 0.85 | FURIN (0.40) | FURINNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL10270090 | 0.84 | FURIN (0.39) | FURINNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178451-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2023-09-28 | — | — | WO | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209591-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | FURIN 1025/4885NPY5R 461/4885NPY4R 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.